Cargando…

Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis

The pharmacological management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects. The aim of this review is to explore the risk of adverse drug reactions and drug–drug interactions with treatments for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzoli, René, Reginster, Jean-Yves, Boonen, Steven, Bréart, Gérard, Diez-Perez, Adolfo, Felsenberg, Dieter, Kaufman, Jean-Marc, Kanis, John A., Cooper, Cyrus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135835/ https://www.ncbi.nlm.nih.gov/pubmed/21637997 http://dx.doi.org/10.1007/s00223-011-9499-8

Ejemplares similares

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2018)

Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J.A., et al.
Publicado: (2020)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2012)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

European guidance for the diagnosis and management of osteoporosis in postmenopausal women
por: Kanis, J. A., et al.
Publicado: (2008)

Intervention thresholds and diagnostic thresholds in the management of osteoporosis
por: Kanis, John A., et al.
Publicado: (2022)

Health Technology Assessment in Osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2013)

Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11): A position paper of the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ESCEO) and the International Osteoporosis and Other Skeletal Diseases Foundation (IOF)
por: Rabenda, Véronique, et al.
Publicado: (2015)

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
por: Bruyère, Olivier, et al.
Publicado: (2008)

Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO)
por: Cianferotti, Luisella, et al.
Publicado: (2017)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
por: Fuggle, N. R., et al.
Publicado: (2020)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
por: Bock, Oliver, et al.
Publicado: (2008)

Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
por: Bruyère, Olivier, et al.
Publicado: (2017)

A reappraisal of generic bisphosphonates in osteoporosis
por: Kanis, J. A., et al.
Publicado: (2011)

Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis
por: Beaudart, Charlotte, et al.
Publicado: (2023)

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
por: Rozenberg, S., et al.
Publicado: (2020)

Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment
por: Hiligsmann, Mickaël, et al.
Publicado: (2014)

Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
por: Rozenberg, Serge, et al.
Publicado: (2015)

Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis
por: Lorentzon, Mattias, et al.
Publicado: (2019)

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis
por: Honvo, Germain, et al.
Publicado: (2019)

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
por: Reginster, J-Y., et al.
Publicado: (2011)

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
por: Body, J.-J., et al.
Publicado: (2010)

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
por: Rizzoli, R., et al.
Publicado: (2010)

An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
por: Li, Nannan, et al.
Publicado: (2020)

The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation
por: Cianferotti, Luisella, et al.
Publicado: (2017)

Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2013)

Commentary on guidelines on postmenopausal osteoporosis - Indian Menopause Society
por: Kanis, John
Publicado: (2013)

Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2022)

Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
por: Ferrari, Serge, et al.
Publicado: (2016)

Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
por: Pavelka, Karel, et al.
Publicado: (2016)

Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis
por: Rizzoli, René, et al.
Publicado: (2010)

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2023)

Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies
por: Veronese, Nicola, et al.
Publicado: (2022)

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database
por: Breart, G., et al.
Publicado: (2009)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art—outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
por: Diez-Perez, Adolfo, et al.
Publicado: (2019)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

A clinical therapeutic protein drug–drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis
por: Jang, Graham, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a17l1q41kpaqng4md0bvas6um1